Trinity Biotech PLC (TRIB) Q2 2024 Earnings Call Highlights: Strong Point-of-Care Growth Amidst ...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Trinity Biotech Reports Positive Pre-pivotal Study Data For Continuous Glucose Monitor Technology
Express News | Trinity Biotech PLC - Second European Pre-Pivotal Trial Scheduled for Q4 2024
Express News | Trinity Biotech PLC - Refined Sensor Achieves Favourable Mard Compared to Previous Device
Express News | Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology
Trinity Biotech Reports Strong Asset Growth
Trinity Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Trinity Biotech Affirms Board Appointments
European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday
Trinity Biotech Acquires Metabolomics Diagnostics; Shares Rise After Hours
Trinity Acquires Preeclampsia Test Developer Metabolomics
Trinity Biotech: Dr. Robin Tuytten Will Join Management Team and Continue to Serve as Director of Metabolomic Diagnostics >TRIB
Trinity Biotech's Deal Values Metabolomics Diagnostics With An Enterprise Value Of ~$1.3M With The Consideration Consisting Of Just Over 270,000 Trinity Biotech's ADS With The Balance Of Consideration Being In Cash And The Assumption Of Liabilities
Trinity Biotech: Metabolomics Diagnostics Developed Test, PrePsia, to Accurately Predict Risk of Preeclampsia in Pregnant Women >TRIB
Trinity Biotech: PrepSia Will Be Commercialized in U.S. Market in 2025 Through NY-based Immco Reference Laboratory >TRIB
Trinity Biotech: Consideration Consists of Just Over 270,000 Trinity Biotech Plc's ADS With Balance in Cash and Assumption of Liabilities
Express News | Trinity Biotech PLC - Prepsia Test to Be Commercialized in U.S. in 2025
Express News | Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
Trinity Biotech Launches Over $1M ADS Offering